Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
Cancers · 26.04.2023 · 15 (9) · 2471
DOI: 10.3390/cancers15092471 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.04.2023. Verfasst von Elena Muraro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italia, Ministero della Salute Ricerca Corrente, CRO Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Increasing evidence pinpoints metronomic chemotherapy, a frequent and low dose drug administration with no prolonged drug-free intervals, as a potential tool to fight certain types of cancers. The primary identified targets of metronomic chemotherapy were the tumor endothelial cells involved in angiogenesis. After this, metronomic chemotherapy has been shown to efficiently target the heterogeneous population of tumor cells and, more importantly, elicit the innate and adaptive immune system reverting the “cold” to ”hot” tumor immunologic phenotype. Although metronomic chemotherapy is primarily used in the context of a palliative setting, with the development of new immunotherapeutic drugs, a synergistic therapeutic role of the combined metronomic chemotherapy and immune checkpoint inhibitors has emerged at both the preclinical and clinical levels. However, some aspects, such as the dose and the most effective scheduling, still remain unknown and need further investigation. Here, we summarize what is currently known of the underlying anti-tumor effects of the metronomic chemotherapy, the importance of the optimal therapeutic dose and time-exposure, and the potential therapeutic effect of the combined administration of metronomic chemotherapy with checkpoint inhibitors in preclinical and clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Radiation Oncology Department, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Medical Oncology Department, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
ORCID-Profile: Elena Muraro, Lorenzo Vinante, Alessandra Bearz, Agostino Steffan
Förderung
- Ministero della Salute, Italia
- Ministero della Salute Ricerca Corrente
- CRO Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Zitieren
APA
Muraro, E., Vinante, L., Fratta, E., Bearz, A., Höfler, D., Steffan, A., & Baboci, L. (2023). Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors. Cancers, 15(9), 2471. https://doi.org/10.3390/cancers15092471
Vancouver
Muraro E, Vinante L, Fratta E, Bearz A, Höfler D, Steffan A, et al. Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors. Cancers. 2023;15(9):2471. doi:10.3390/cancers15092471
BibTeX
@article{Muraro2023,
author = {Muraro, Elena and Vinante, Lorenzo and Fratta, Elisabetta and Bearz, Alessandra and Höfler, Daniela and Steffan, Agostino and Baboci, Lorena},
title = {Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors},
journal = {Cancers},
year = {2023},
volume = {15},
number = {9},
pages = {2471},
doi = {10.3390/cancers15092471}
}
EUVIMED